| Turner Syndrome

Norditropin vs Genotropin

Side-by-side clinical, coverage, and cost comparison for turner syndrome.

Deep comparison between: Norditropin vs Genotropin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGenotropin has a higher rate of injection site reactions vs Norditropin based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Genotropin but not Norditropin, including UnitedHealthcare

Category

Norditropin

Genotropin

At A Glance

RouteSC injection

FrequencyDaily

ClassRecombinant human growth hormone

RouteSC injection

Frequency6-7 times weekly

ClassRecombinant human growth hormone

Indications

Noonan Syndrome
Turner Syndrome
Prader-Willi Syndrome

Somatotropin deficiency
Prader-Willi Syndrome
Growth failure
Turner Syndrome
Growth Disorders

Dosing

Pediatric GHD 0.17-0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Noonan Syndrome Up to 0.46 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Turner Syndrome, SGA, ISS Up to 0.47 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into equal doses given 6 or 7 days per week.

Adult GHD (non-weight-based) Initiate at approximately 0.2 mg/day SC (range 0.15-0.3 mg/day); increase every 1-2 months by 0.1-0.2 mg/day based on clinical response and IGF-1 concentrations.

Adult GHD (weight-based) Initiate at 0.004 mg/kg/day SC; increase to a maximum of 0.016 mg/kg/day; not recommended for obese patients.

Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.

Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.

Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Active malignancy
Hypersensitivity to somatropin or any excipient of NORDITROPIN
Active proliferative or severe non-proliferative diabetic retinopathy
Pediatric patients with closed epiphyses

Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses (for growth promotion in pediatric patients)

Drug Interactions

267View drug interactions

Adverse Reactions

Most common (>=5%, adult onset GHD) Peripheral edema, edema, arthralgia, leg edema, myalgia, non-viral infection, paraesthesia, skeletal pain, headache, bronchitis, flu-like symptoms, hypertension, gastroenteritis, increased sweating, abnormal glucose tolerance, laryngitis, type 2 diabetes mellitus

Serious Increased mortality in acute critical illness, sudden death in pediatric PWS patients, neoplasms, intracranial hypertension, severe hypersensitivity reactions, fluid retention, slipped capital femoral epiphysis, pancreatitis

Postmarketing Anaphylactic reactions, angioedema, increase in cutaneous nevi, hypothyroidism, gynecomastia, hyperglycemia, osteonecrosis, increased blood alkaline phosphatase, decreased serum T4, pancreatitis, leukemia

Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, otitis media and cardiovascular disorders in Turner syndrome, pancreatitis

Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome

Pharmacology

Recombinant human growth hormone (somatropin) binds to dimeric GH receptors on target tissue cell membranes, triggering intracellular signal transduction and induction of GH-dependent proteins including IGF-1, IGFBP-3, and acid-labile subunit, which stimulate chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal linear growth via effects on epiphyses of long bones.

Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Norditropin